MedMira (MedMira) Debt-to-Equity : -0.56 (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Debt-to-Equity?

MedMira's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $4.68 Mil. MedMira's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $1.97 Mil. MedMira's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $-11.98 Mil. MedMira's debt to equity for the quarter that ended in Jan. 2024 was -0.56.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MedMira's Debt-to-Equity or its related term are showing as below:

MMIRF' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.78 Med: -0.77 Max: -0.56
Current: -0.56

During the past 13 years, the highest Debt-to-Equity Ratio of MedMira was -0.56. The lowest was -1.78. And the median was -0.77.

MMIRF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs MMIRF: -0.56

MedMira Debt-to-Equity Historical Data

The historical data trend for MedMira's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Debt-to-Equity Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-Equity

Get a 7-Day Free Trial

-0.64

-0.77

-0.73

-0.67

-0.62

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															-0.66	-0.66	-0.62	-0.59	-0.56

Competitive Comparison of MedMira's Debt-to-Equity

For the Biotechnology subindustry, MedMira's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MedMira's Debt-to-Equity falls into.

MedMira Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MedMira's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.779	+	2.238)	/	-11.378
	=	-0.62

MedMira's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.682	+	1.969)	/	-11.98
	=	-0.56

MedMira (OTCPK:MMIRF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MedMira Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MedMira's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.